Phase 1b clinical trial of SNDX-6352 in combination with immune checkpoint inhibitor durvalumab for the treatment of solid tumours.
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Durvalumab (Primary) ; UCB 6352 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 07 Feb 2018 New trial record
- 01 Feb 2018 According to Syndax Pharmaceuticals media release, trial is expected to start in the first half of 2018.